Boehringer Ingelheim registers Phase 1 bioequivalence trial for survodutide formulations
A new trial comparing two subcutaneous formulations of survodutide was listed on ClinicalTrials.gov, with recruitment not yet underway.
Boehringer Ingelheim registered one new early-stage study this week involving its investigational drug survodutide.
- Boehringer Ingelheim registered a Phase 1 trial, "Bioequivalence of Two Survodutide (BI 456906) Formulations (A Versus D1) Via Subcutaneous Administration After Multiple Doses," testing whether formulation A and formulation D1 are bioequivalent after multiple-dose subcutaneous administration in healthy male and female participants with overweight or obesity1. The study is not yet recruiting, with an estimated start of December 3, 2026 and estimated primary completion of October 31, 20271, and plans to enroll 80 participants1.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.